Welcome to our dedicated page for Enovis news (Ticker: ENOV), a resource for investors and traders seeking the latest updates and insights on Enovis stock.
Enovis Corporation (NYSE: ENOV) is described in its public materials as an innovation-driven medical technology growth company with a focus on orthopedics, musculoskeletal care and clinically differentiated solutions. The Enovis news stream on this page highlights how the company communicates with the market through earnings announcements, portfolio updates and participation in major healthcare and investor conferences.
Investors following ENOV news will see quarterly financial results releases, where Enovis reports performance for its Prevention & Recovery (P&R) and Reconstructive (Recon) segments and discusses trends such as organic sales growth, adjusted EBITDA and adjusted net income. These updates often include management commentary on commercial execution, innovation priorities, operational discipline and financial outlook.
Company news also covers strategic and portfolio actions, such as the sale of a diabetic footcare business from the Prevention & Recovery segment, which Enovis has described as sharpening its focus on core strengths in P&R. In addition, releases may address changes in leadership roles and organizational structure, reflecting how the company supports its next phase of growth and operational efficiency.
Another key element of Enovis-related news involves investor relations activities, including announcements about conference presentations, fireside chats and webcasts at healthcare and growth conferences, as well as participation in events like the J.P. Morgan Healthcare Conference. These items typically provide webcast details and indicate how investors can access presentations and replays.
For anyone researching ENOV, this news page offers a centralized view of the company’s earnings releases, strategic updates and investor event participation. It is a useful resource for tracking how Enovis describes its progress in medical technology, orthopedics and its Prevention & Recovery and Reconstructive businesses over time.
Enovis (NYSE: ENOV) completed the sale of its Dr. Comfort footcare diabetic shoe business to Promus Equity Partners for up to $60 million in cash, comprising an $45 million upfront payment and up to $15 million in milestone payments.
The company said the divestiture sharpens focus on its Prevention & Recovery franchise, aims to expand margins, enhance profitability, and accelerate debt reduction. Enovis will discuss strategic details on its Q3 results call on Nov 6, 2025 at 8:30 am ET. Promus is a multi-family asset manager with approximately $2.7 billion under management. Citizens Capital Markets & Advisory and Tucker Ellis LLP advised Enovis.
Enovis Corporation (NYSE:ENOV), a medical technology growth company, has announced a schedule change for its presentation at the Baird 2025 Global Healthcare Conference. The company will now present on Wednesday, September 10th, 2025 at 2:35 p.m. ET. Investors can access both the live audio webcast and replay through the Events and Presentations section under the Investors tab on Enovis' website.
Enovis Corporation (NYSE: ENOV), a medical technology growth company, has announced its upcoming participation in three major investor conferences:
- Canaccord Genuity 45th Annual Growth Conference on August 13th at 8:30 a.m. ET
- Wells Fargo Healthcare Conference on September 3rd at 2:15 p.m. ET
- Baird 2025 Global Healthcare Conference on September 10th at 3:10 p.m. ET
Live audio webcasts and replays will be accessible through the Investors section of the company's website under Events and Presentations.
Enovis (NYSE:ENOV) reported strong Q2 2025 financial results with net sales of $565 million, representing a 7% reported growth and 5% organic growth year-over-year. The company's Reconstructive segment grew 11% on a reported basis, while Prevention & Recovery (P&R) increased 5%.
Despite positive sales growth, Enovis recorded a net loss of $37 million (6.5% of sales) and adjusted EBITDA of $97 million (17.2% of sales). The company updated its 2025 guidance, raising revenue expectations to $2.245-2.275 billion and adjusted EPS guidance to $3.05-3.20.
Enovis Corporation (NYSE: ENOV), a medical technology growth company, will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. ET. The company will release its earnings report earlier that morning.
Investors can access the live webcast through Enovis' website investor section, and those wishing to participate in the call can dial (833) 685-0901. A presentation and replay of the call will be available on the company's website following the event.
Enovis Corporation (NYSE: ENOV) reported strong Q1 2025 financial results with net sales of $559 million, representing an 8% growth on a reported basis and 9% on a comparable basis. The company's Reconstructive segment showed impressive growth of 11% year-over-year, while P&R segment grew 5%. However, Enovis reported a net loss from continuing operations of $56 million (-$0.98 per share).
The company achieved an adjusted EBITDA of $99 million (17.7% of sales), marking a 160 basis point improvement from the previous year. Enovis updated its 2025 guidance, raising revenue expectations to $2.22-2.25 billion but lowering adjusted EBITDA forecast to $385-395 million due to $20 million in tariff-related impact. The company also announced the appointment of Damien McDonald as CEO, effective May 12th, 2025.
Enovis (NYSE: ENOV) has announced it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time. The company will release its earnings press release earlier that morning. A presentation and webcast will be accessible through the 'Investors' section of Enovis' website.
Investors can participate by dialing (833) 335-0887 with Access Code: 482081, or preregister through a provided link. A replay of the call will be made available on the company's website later that day.
Enovis (NYSE: ENOV) has announced the appointment of Damien McDonald as its new Chief Executive Officer, effective May 12, 2025. McDonald, who brings over 35 years of medical device industry experience, will succeed Matt Trerotola, who is retiring. McDonald will also join the Enovis Board of Directors after the 2025 Annual Meeting on May 21.
McDonald previously served as CEO of LivaNova, where he improved growth, profitability, and shareholder value. His experience includes leadership roles at Danaher, Zimmer, and Johnson & Johnson's Ethicon unit. The company has reiterated its Q1 2025 guidance with expected revenues of $555-563 million and adjusted EBITDA of $97-100 million.
Sharon Wienbar, currently Lead Independent Director, will become Board Chair following Trerotola's retirement. The company will address questions about the transition during its Q1 2025 earnings call on May 8, 2025.
Enovis (NYSE: ENOV) will showcase its expanding foot and ankle solutions portfolio at the ACFAS Annual Scientific Conference in Phoenix from March 27-30, 2025. The company will highlight several innovative products, including the new Tarsoplasty Percutaneous Lapidus Correction System for bunionectomy procedures.
The exhibition will feature advanced solutions such as OssiGraft Prime viable bone matrix allografts, Aircast AirSelect Elite pneumatic walking boot, Velocity+ proximal extension cuff, and Regeneration OL1000 bone growth stimulator. New research comparing the Arsenal Foot Plating System's screw angulation will also be presented.
The company will host two special events: 'Phoenix Rising: Foot & Ankle Edition' on March 28 and a Flatfoot/MIS Techniques Workshop on March 26.